Temodar and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temodar (temozolomide) and Ibrance (palbociclib). Common drug interactions include fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Temodar and Ibrance. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Temodar?

Temodar has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 6,683 Temodar users. Check the latest studies of Temodar.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

12 people who take Temodar and Ibrance together, and have interactions are studied.

What are the common drug interactions of Temodar and Ibrance, by gender? *:

female:

n/a

male:

Fatigue (feeling of tiredness)
Syncope (loss of consciousness with an inability to maintain postural tone)
Hypotension (abnormally low blood pressure)
Joint stiffness
Memory impairment
Weight decreased
Dizziness postural
Ear pain
Hand fracture
Loss of consciousness

What are the common drug interactions of Temodar and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Death
White blood cell count decreased

40-49:

n/a

50-59:

n/a

60+:

Balance disorder
Fatigue (feeling of tiredness)
Fall
Gait disturbance
Hand fracture
Hypotension (abnormally low blood pressure)
Joint stiffness
Loss of consciousness
Memory impairment
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

What are the existing conditions these people have? *

Pain: 3 people, 25.00%
Malignant Pituitary Tumor: 3 people, 25.00%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 2 people, 16.67%
Depression: 2 people, 16.67%
Breast Cancer Metastatic: 2 people, 16.67%
Blood Testosterone Decreased: 2 people, 16.67%
Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 1 person, 8.33%
Patellofemoral Pain Syndrome (pain in the front of the knee): 1 person, 8.33%
Orthostatic Hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up): 1 person, 8.33%
Fainting (loss of consciousness and postural tone): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Temodar and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously